[1]夏延,汪四海,李中南,等.名中医李中南辨证治疗桥本甲状腺炎经验撷菁[J].陕西中医,2026,(3):388-391.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.019]
 XIA Yan,WANG Sihai,LI Zhongnan,et al.Essence of professor LI Zhongnan’s experience in treating hashimoto’s thyroiditis with dialectical theory[J].,2026,(3):388-391.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.019]
点击复制

名中医李中南辨证治疗桥本甲状腺炎经验撷菁

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年3期
页码:
388-391
栏目:
名中医经验
出版日期:
2026-03-05

文章信息/Info

Title:
Essence of professor LI Zhongnan’s experience in treating hashimoto’s thyroiditis with dialectical theory
作者:
夏延1汪四海234李中南2桂依萍1张秉芳1朱靖珂1
(1.安徽中医药大学,安徽 合肥 230031;2.安徽中医药大学第一附属医院,安徽 合肥 230031;3.新安医学教育部重点实验室,安徽 合肥 230038;4.安徽省中医药科学院中医药防治糖尿病研究所,安徽 合肥 230031)
Author(s):
XIA Yan1WANG Sihai234LI Zhongnan2GUI Yiping1ZHANG Bingfang1ZHU Jingke1
(1.Anhui University of Chinese Medicine,Hefei 230031,China;2.The First Hospital of Anhui University of Chinese Medicine,Hefei 230031,China;3.Xin’an Medical Ministry of Education Key Laboratory,Hefei 230038,China; 4.Institute of Chinese Medicine Prevenion and Treatment of Diabetes,Anhui Academy of Chinese Medical Science,Hefei 230031,China)
关键词:
李中南 桥本甲状腺炎辨证分型治疗经验阴阳调和标本同治
Keywords:
LI ZhongnanHashimoto thyroiditisSyndrome differentiationTreatment experienceHarmony of yin and yangTreating both the root and branch
分类号:
R 581.4
DOI:
DOI:10.3969/j.issn.1000-7369.2026.03.019
文献标志码:
A
摘要:
桥本甲状腺炎(HT)是临床上常见的甲状腺疾病,该病后期多半会转归为甲状腺功能减退症,早期干预可有效控制颈部粗大,降低甲状腺抗体指标,改善患者生活质量。本文总结李中南主任辨证治疗桥本甲状腺炎的经验。针对本病,李中南主任抓住核心病机,认为其发病与气虚,肝、脾、肾失调密切相关;气虚、痰凝、血瘀是其重要病理因素。李师重视中医药辨证论治,将此病分为肝郁脾虚型、气虚痰阻型、痰瘀互结型、脾肾阳虚四型,临床上辨病与辨证相结合,疗效显著。
Abstract:
Hashimoto's thyroiditis (HT) is a relatively common thyroid disease in clinical practice,and most of the late stages of the disease will naturally regress to hypothyroidism,and early intervention can effectively control neck enlargement and improve the quality of life of patients.This article summarises the experience of Director LI Zhongnan in treating Hashimoto's thyroiditis.To address this disease,Director LI Zhongnan captured the core pathogenesis,arguing that most of its sufferers have yang-qi deficiency,and that the morbidity is closely related to the liver,spleen,and kidneys,and that qi deficiency,qi stagnation,phlegm condensation,and blood stasis are important pathological factors.Stressing on the identification and treatment of Chinese medicine,LI classified the disease into four types:liver-depression and spleen-deficiency type,qi deficiency and phlegm obstruction type,phlegm and blood stasis type,and spleen and kidney yang deficiency,and the combination of clinical diagnosis of the disease and identification of the disease resulted in remarkable therapeutic effects.

参考文献/References:

[1]CATUREGLI P,DE REMIGIS A,CHUANG K,et al.Hashimoto’s thyroiditis:Celebrating the centennial through the lens of the Johns Hopkins hospital surgical pathology records[J].Thyroid,2013,23(2):142-150.
[2]田昌平,梁栋.桥本氏甲状腺炎之中医命名初探[J].中医药导报,2018,24(12):45-46,53.
[3]闻璐,周慧敏,向楠.向楠辨治桥本甲状腺炎合并甲状腺功能减退经验[J].湖北中医药大学学报,2022,24(2):115-117.
[4]高天舒,倪青.甲状腺结节病证结合诊疗指南(2022)[J].中医杂志,2023,64(4):425-432.
[5]任永丽,褚月颉,崔翰博,等.张曾譻“从脑论治”桥本甲状腺炎经验探析[J].山西中医,2025,41(2):4-6.
[6]李冉,任继鹏,范会军,等.八珍汤在甲状腺结节细针穿刺术后的应用价值[J].陕西中医,2019,40(6):777-780.
[7]崔伟更,张兰.慢性淋巴细胞性甲状腺炎亚临床期病机探析[J].陕西中医,2021,42(5):632-634.
[8]邓俊林,王小平,朱小雨,等.消瘿方联合微波消融术治疗桥本甲状腺炎伴结节疗效研究[J].陕西中医,2022,43(3):309-313.
[9]胡雪淇,闫梦如,杨小雪,等.名中医李惠林从“燮理阴阳”论治桥本甲状腺炎经验[J].陕西中医,2025,46(5):676-679,684.
[10]王聪慧.桥本氏甲状腺炎的情志调查及中医证型的相关性研究[D].北京:北京中医药大学,2024.
[11]窦德梅,李中南.李中南辨证治疗甲状腺功能亢进症经验[J].陕西中医药大学学报,2019,42(1):20-22.
[12]谈啸.细针穿刺细胞学联合BRAF基因检测对桥本甲状腺炎合并甲状腺结节良恶性的诊断价值[D].南京:南京医科大学,2023.
[13]李翔.超声检查在桥本氏甲状腺炎伴发结节良恶性鉴别诊断中的应用[J].医疗装备,2025,38(13):74-75,78.
[14]白光锐,苏智雄.TSH与TAPOAb检测在桥本甲状腺炎与甲状腺乳头状癌鉴别诊断中的应用价值[J].中国医学文摘(耳鼻咽喉科学),2020,35(4):267-269.
[15]张朋宇.甲状腺乳头状癌合并桥本甲状腺炎的临床特征及淋巴结转移危险因素分析[D].郑州:郑州大学,2022.
[16]高净,邱爽.三种超声分类系统评估桥本甲状腺炎合并甲状腺结节良恶性效能研究[J].陕西医学杂志,2024,53(2):207-211,216.
[17]吴海,魏华.魏华教授分期辨治桥本甲状腺炎经验总结[J].西部中医药,2024,37(8):51-54.
[18]黄太发,龚红卫.基于网络药理学探究消瘰丸治疗甲状腺结节作用机制[J].中西医结合研究,2024,16(4):240-244.
[19]李梦然,张楚欣,方琪,等.基于网络药理学和动物实验初步探讨消瘰丸联合党参治疗甲状腺肿的作用机制[J].世界中西医结合杂志,2024,19(9):1783-1795.
[20]田硕,王丽娜,王芙蓉.消瘰丸治疗甲状腺疾病的研究[J].中国中医基础医学杂志,2023,29(10):1773-1776.
[21]梁伟,孙禹,陈丽新,等.消瘰丸基于PI3K/Akt/mTORC1通路对实验性甲状腺肿大鼠的干预机制[J].中国实验方剂学杂志,2022,28(8):30-36.
[22]杨伟金,王婷婷,朱燕舞,等.基于数据挖掘研究含白术-茯苓药对方剂的组方规律[J].中国现代应用药学,2024,41(14):1980-1988.
[23]郇靖,苗德光,陆玉成,等.基于网络药理学的柴胡-枳壳配伍治疗功能性消化不良的机制研究[J].中国中医药现代远程教育,2024,22(9):82-85.
[24]杨甫臣,张世超.基于网络药理学的“海藻-昆布”治疗甲状腺肿的作用机制研究[J].中国医药导报,2021,18(5):133-138,197.
[25]刘洋靖,马朝群,朱太阳,等.桂枝茯苓丸“异病同治”甲状腺结节、乳腺结节及子宫肌瘤网络药理学机制研究[J].中国中医药信息杂志,2022,29(3):17-25.

备注/Memo

备注/Memo:
国家自然科学基金资助项目(82474431);安徽省李中南名医工作室建设项目(安徽省卫健委中发展〔2020〕10号);第三批安徽省名中医学术经验继承工作室项目(皖中医药函〔2025〕10号);安徽省高校协同创新项目(GXXT-2020-025);安徽省卫生健康委员会青年基金资助项目(AHWJ2023A30274);安徽省高校自然科学研究重点项目(2022AH050488);新安医学教育部重点实验室开放课题重点项目(2022XAYX05);安徽省研究生教育质量工程项目(2024ZYXWJXALK124);大
更新日期/Last Update: 2026-03-05